148 related articles for article (PubMed ID: 26170557)
1. Absorbed dose assessment of (177)Lu-zoledronate and (177)Lu-EDTMP for human based on biodistribution data in rats.
Yousefnia H; Zolghadri S; Jalilian AR
J Med Phys; 2015; 40(2):102-8. PubMed ID: 26170557
[TBL] [Abstract][Full Text] [Related]
2. Production, Quality Control and Pharmacokinetic Studies of (177)Lu-EDTMP for Human Bone Pain Palliation Therapy Trials.
Bahrami-Samani A; Anvari A; Jalilian AR; Shirvani-Arani S; Yousefnia H; Aghamiri MR; Ghannadi-Maragheh M
Iran J Pharm Res; 2012; 11(1):137-44. PubMed ID: 25317195
[TBL] [Abstract][Full Text] [Related]
3. Comparative Therapeutic Efficacy of
Sharma S; Singh B; Koul A; Mittal BR
Front Med (Lausanne); 2017; 4():46. PubMed ID: 28507988
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity.
Kamaldeep ; Thapa P; Wanage G; Tervankar S; Kaisar S; Ranade R; Basu S; Das T; Banerjee S
Nucl Med Commun; 2021 Oct; 42(10):1076-1084. PubMed ID: 34528928
[TBL] [Abstract][Full Text] [Related]
5. Production, biodistribution assessment and dosimetric evaluation of (177)Lu-TTHMP as an agent for bone pain palliation.
Zolghadri S; Yousefnia H; Jalilian AR; Ghannadi-Maragheh M
Asia Ocean J Nucl Med Biol; 2015; 3(1):35-42. PubMed ID: 27408879
[TBL] [Abstract][Full Text] [Related]
6. Estimated human absorbed dose of ¹⁷⁷Lu-BPAMD based on mice data: Comparison with ¹⁷⁷Lu-EDTMP.
Yousefnia H; Zolghadri S; Shanehsazzadeh S
Appl Radiat Isot; 2015 Oct; 104():128-35. PubMed ID: 26163291
[TBL] [Abstract][Full Text] [Related]
7. Formulation, preclinical evaluation, and preliminary clinical investigation of an in-house freeze-dried EDTMP kit suitable for the preparation of 177Lu-EDTMP.
Das T; Sarma HD; Shinto A; Kamaleshwaran KK; Banerjee S
Cancer Biother Radiopharm; 2014 Dec; 29(10):412-21. PubMed ID: 25409337
[TBL] [Abstract][Full Text] [Related]
8. Comparative studies on the potential use of
Zakaly HMH; Mostafa MYA; Deryabina D; Zhukovsky M
Int J Radiat Biol; 2020 Jun; 96(6):779-789. PubMed ID: 32043915
[No Abstract] [Full Text] [Related]
9. Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent.
Máthé D; Balogh L; Polyák A; Király R; Márián T; Pawlak D; Zaknun JJ; Pillai MR; Jánoki GA
Nucl Med Biol; 2010 Feb; 37(2):215-26. PubMed ID: 20152721
[TBL] [Abstract][Full Text] [Related]
10. Studies on the Labeling of Ethylenediaminetetramethylene Phosphonic Acid, Methylene Diphosphonate, Sodium Pyrophosphate and Hydroxyapatite with Lutetium-177 for use in Nuclear Medicine.
Abbasi IA
World J Nucl Med; 2015; 14(2):95-100. PubMed ID: 26097419
[TBL] [Abstract][Full Text] [Related]
11. Production, quality control, and determination of human absorbed dose of no carrier added
Salek N; Mehrabi M; Shirvani Arani S; Bahrami Samani A; Erfani M; Vosoghi S; Ghannadi Maragheh M; Shamsaei M
J Labelled Comp Radiopharm; 2017 Jan; 60(1):20-29. PubMed ID: 27862203
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study.
Yuan J; Liu C; Liu X; Wang Y; Kuai D; Zhang G; Zaknun JJ
Clin Nucl Med; 2013 Feb; 38(2):88-92. PubMed ID: 23334120
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Ready to Use Kit Formulation of EDTMP for the Preparation of 177Lu-EDTMP as a Bone Palliation Radiopharmaceutical.
Mercanoglu G; Zilbeyaz K; Arslan N
Curr Radiopharm; 2023; 16(1):38-43. PubMed ID: 35899954
[TBL] [Abstract][Full Text] [Related]
14. Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation.
Abbasi IA
Nucl Med Biol; 2011 Apr; 38(3):417-25. PubMed ID: 21492790
[TBL] [Abstract][Full Text] [Related]
15. Metastatic Bone Pain Palliation using (177)Lu-Ethylenediaminetetramethylene Phosphonic Acid.
Alavi M; Omidvari S; Mehdizadeh A; Jalilian AR; Bahrami-Samani A
World J Nucl Med; 2015; 14(2):109-15. PubMed ID: 26097421
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution and post-therapy dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
EJNMMI Res; 2019 Nov; 9(1):102. PubMed ID: 31781962
[TBL] [Abstract][Full Text] [Related]
17. (170)Tm-EDTMP: a potential cost-effective alternative to (89)SrCl(2) for bone pain palliation.
Das T; Chakraborty S; Sarma HD; Tandon P; Banerjee S; Venkatesh M; Pillai MR
Nucl Med Biol; 2009 Jul; 36(5):561-8. PubMed ID: 19520297
[TBL] [Abstract][Full Text] [Related]
18. Production, quality control, biodistribution assessment and preliminary dose evaluation of (177)Lu-PDTMP as a possible bone palliative agent.
Yousefnia H; Jalilian AR; Zolghadri S; Ghannadi-Maragheh M
Nucl Med Commun; 2014 Jan; 35(1):99-107. PubMed ID: 24162837
[TBL] [Abstract][Full Text] [Related]
19.
Askari E; Harsini S; Vahidfar N; Divband G; Sadeghi R
Cancer Biother Radiopharm; 2021 Jun; 36(5):383-390. PubMed ID: 33259726
[No Abstract] [Full Text] [Related]
20. Preliminary results of biodistribution and dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
